The EV-303 trial that led to the FDA approval of perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible bladder cancer patients in now published in NEJM.  We discuss the results and ponder potential future changes to treating bladder cancer in the future.

Urinary diversion surgeries: https://jamanetwork.com/journals/jamaoncology/fullarticle/2842595

Rezatapopt and Colchicine for Trametnib/Dabrafenib Pyrexia

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.